RB1

Retinoblastoma-associated protein · P06400 · RB1 on Sugi Atlas →

3,780 patent compounds predicted against RB1, 2,828 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5520186	0.67	11/20
Hydrochloric Acid (SCHEMBL4162233)	1.00	10/20
SCHEMBL4196380	1.00	10/20
Hydrochloric Acid (SCHEMBL4153425)	0.79	10/20
SCHEMBL4188706	0.78	10/20
SCHEMBL5456627	0.65	10/20
SCHEMBL5454769	0.60	10/20
SCHEMBL5456571	0.69	9/20
SCHEMBL4191431	0.62	9/20
Hydrochloric Acid (SCHEMBL4365291)	0.50	9/20
Hydrochloric Acid (SCHEMBL4162946)	0.63	8/20
SCHEMBL5463397	0.61	8/20
Hydrochloric Acid (SCHEMBL4157051)	0.59	8/20
Hydrochloric Acid (SCHEMBL4160307)	0.59	8/20
SCHEMBL4194091	0.58	8/20
Hydrochloric Acid (SCHEMBL4148087)	0.55	8/20
Hydrochloric Acid (SCHEMBL4153475)	0.55	8/20
SCHEMBL4191135	0.54	8/20
SCHEMBL4196258	0.54	8/20
SCHEMBL6033064	0.50	8/20

Clinical trials — most relevant to RB1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma	PHASE3	COMPLETED
Avelumab, Palbociclib and Axitinib in Advanced RCC	PHASE2	WITHDRAWN
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)	PHASE2	RECRUITING
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers	PHASE1/PHASE2	COMPLETED
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer	PHASE2	COMPLETED
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC	PHASE2	COMPLETED
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors	PHASE1	COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma	nan	COMPLETED
Retinoblastoma Patient Clinical Database and Tissue Repository	nan	RECRUITING
Retinoblastoma Biomarker Study	nan	COMPLETED
New Strategies to Detect Cancers in Carriers of Mutations in RB1	nan	COMPLETED
Molecular Analysis of Retinoblastoma	nan	COMPLETED
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients	nan	RECRUITING
Trilateral Retinoblastoma: Incidence and Outcomes	nan	RECRUITING
Studying Health Outcomes After Treatment in Patients With Retinoblastoma	nan	RECRUITING
Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals	nan	UNKNOWN
Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors	nan	ENROLLING_BY_INVITATION
Retinoblastoma Consolidation in Egyptians	nan	NOT_YET_RECRUITING
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers	nan	COMPLETED
Genetic Analysis of Hereditary Prostate Cancer	nan	COMPLETED
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study	nan	COMPLETED
Clinical Profile of Skin Aging Based on Dermoscopy Photoaging Scale and Glogau Scale - Study of Leucocyte Telomere Length, Biomarker P16, and Body Mass Index	nan	NOT_YET_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Collecting and Storing Tissue From Young Patients With Cancer	nan	COMPLETED
Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a RB1 binder may also engage these)

Protein	Name	Similarity
P13405	—	0.997	P13405 →
Q90600	—	0.995	Q90600 →
Q9SXN6	—	0.990	Q9SXN6 →
Q24472	—	0.989	Q24472 →
Q8H0J6	—	0.989	Q8H0J6 →
G5EDT1	—	0.988	G5EDT1 →
B5E0H4	—	0.987	B5E0H4 →
Q9HDW4	—	0.987	Q9HDW4 →
A8WTE8	—	0.987	A8WTE8 →
Q2R374	—	0.987	Q2R374 →
Q6GM71	—	0.986	Q6GM71 →
G5EFD2	—	0.986	G5EFD2 →
G5EDY0	—	0.986	G5EDY0 →
Q750S2	—	0.986	Q750S2 →
Q8STE5	—	0.986	Q8STE5 →
A9SVH7	—	0.986	A9SVH7 →
Q8IP99	—	0.986	Q8IP99 →
P19736	—	0.986	P19736 →
Q21037	—	0.985	Q21037 →
A6ZP10	—	0.985	A6ZP10 →
KAT8	Histone acetyltransferase KAT8	0.985	landscape →
A8XEZ1	—	0.985	A8XEZ1 →
Q6C710	—	0.985	Q6C710 →
B4GH42	—	0.985	B4GH42 →
P30630	—	0.985	P30630 →
DHX29	ATP-dependent RNA helicase DHX29	0.985	landscape →
P87117	—	0.985	P87117 →
Q9M358	—	0.985	Q9M358 →
Q95RG8	—	0.985	Q95RG8 →
Q19546	—	0.985	Q19546 →